Hong Kong Stock Connect Movement | CStone Pharmaceuticals-B(02616) rose over 7% after earnings. Full-year R&D expenditure increased by 1.3 times year-on-year. Pipeline 2.0 achieved a major breakthrough.

LootboxPhobia

2026-03-27 02:40:08

Abstract generation in progress

Apex Biotechnology (02616) shares surged over 7% after earnings release. As of press time, it was up 5.94%, trading at HKD 7.31, with a turnover of HKD 25.1036 million.

On the news front, Apex Biotechnology announced its annual results, with revenue of approximately RMB 270 million and R&D expenses of about RMB 311.5 million, a year-on-year increase of 131.33%. The company’s pipeline 2.0 made significant progress, with clinical project CS2009 entering Phase II, and providing the world’s first clinical data for a tri-specific antibody targeting PD-1/VEGF/CTLA-4. The company also expanded its therapeutic focus to autoimmune and inflammatory diseases.

In terms of commercialization, the company reached two international agreements for the global commercialization of Simotinib, and received regulatory approval in the EU and UK for its use in treating Phase III non-small cell lung cancer (NSCLC). In China, Tajiwa (Apatinib) successfully renewed its inclusion in the National Medical Insurance Directory, and Pujihua (Pralatrexate) was included in the directory for the first time. These achievements demonstrate the company’s commitment to developing innovative therapies for patients worldwide.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes